6

cyP3A4 inhibitor A TOXICITY OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES DUE TO MUSCARINIC PARA SYMPATHETIC REST All Effects due to sympathetic CAN Also BE USED TRADIRONALLY considered Antidote NO DOSE ADJUSTMENT IN RENAL DISEASE

cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

Download PDF Report

Upload
others
View
5
Download
0

Embed Size (px)

Citation preview

Page 1: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

cyP3A4 inhibitor A TOXICITYOF STATINS

INHIBIT RELEASE OF INFLAMMATORYCYTOKINES

DUE TO MUSCARINIC PARASYMPATHETIC

REST All Effects dueto sympathetic

CAN Also BE USED

TRADIRONALLYconsidered Antidote

NO DOSE ADJUSTMENT IN RENAL DISEASE

Page 2: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

THIopentone Anesthetic

succinylcholineMuscleRelaxant

NOT 1h NSTEM1 ONLY GIVEN IN STEMI

HALFLIFE onlydepend on Vd and CLNot on ABSORPTION

Anticoagulant Like WARFARINCOMPETITIVE INHIBITORXKOR G enzyme

Reduce Yuk dependant clottingfactorslike2,79,10

Ointment produce longlastingeffect

ET iE

Page 3: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

BACTERIOSTATc

INTRACELLUARINUCLEARRECEPTOR

REST All OTHERS GPCR

Page 4: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

o IMAGE FLAGELLATE PIGMENTATION

Page 5: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

BOTH SUPRESS SA and All node

AlwaysProtease inhibitoradded

3 DRUGRegimen is proffered

DEATH due to SPURIOUS DRUG

Min Punishment 10yearsMAX Life imprisonment

POLYVALENT AntiseraIs mainstay forVIPER's TIE

Page 6: cyP3A4 inhibitor A TOXICITY · 2020. 7. 1. · Linagliptin Vildagliptin Saxagliptin Sitagliptin TOXICITY PARA cyP3A4 inhibitor A OF STATINS INHIBIT RELEASE OF INFLAMMATORY CYTOKINES

mom

yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · P-gp CYP3A4, AUC 1.5 1.6 CYP3A4 CYP3A41k P-gp : CYP3A4 P-gp , CYP3A4 P-gp (5mg, (40mg, ) (325mg, (75mg, ( PT, APTT)

yaozh.comzy.yaozh.com › instruct › sms20170707 › 1.pdf · P-gp CYP3A4, AUC 1.5 1.6 CYP3A4 CYP3A41k P-gp : CYP3A4 P-gp , CYP3A4 P-gp (5mg, (40mg, ) (325mg, (75mg, ( PT, APTT)

Documents

Evaluation of Normalization Methods To Predict CYP3A4 ...dmd.aspetjournals.org/content/dmd/44/1/50.full.pdf · Evaluation of Normalization Methods To Predict CYP3A4 Induction in

Evaluation of Normalization Methods To Predict CYP3A4 ...dmd.aspetjournals.org/content/dmd/44/1/50.full.pdf · Evaluation of Normalization Methods To Predict CYP3A4 Induction in

Documents

OncOlOgy - Amazon S3 to the 31% to 49% of patients reported with aprepitant.24 Aprepitant is a moderate CYP3A4 inhibitor, and its use requires a 50% dose reduction in dexamethasone

OncOlOgy - Amazon S3 to the 31% to 49% of patients reported with aprepitant.24 Aprepitant is a moderate CYP3A4 inhibitor, and its use requires a 50% dose reduction in dexamethasone

Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Strong CYP3A4 inhibitors or fluconazole 1,000 mg once daily ; Strong or moderate CYP3A4 inducers : 2,500 mg once daily

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Strong CYP3A4 inhibitors or fluconazole 1,000 mg once daily ; Strong or moderate CYP3A4 inducers : 2,500 mg once daily

Documents

MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT) Multinational Association of Supportive Care in Cancer TM Skin Toxicity Scale (last updated July, 2009)

MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT) Multinational Association of Supportive Care in Cancer TM Skin Toxicity Scale (last updated July, 2009)

Documents

205755Orig1s000 - Food and Drug Administration...strong CYP3A inhibitor, resume the ceritinib dose that was taken prior to initiating the strong CYP3A4 inhibitor. Acid Reducing Agents:

205755Orig1s000 - Food and Drug Administration...strong CYP3A inhibitor, resume the ceritinib dose that was taken prior to initiating the strong CYP3A4 inhibitor. Acid Reducing Agents:

Documents

ANEXA I REZUMATUL CARACTERISTICILOR … · Administrare concomitentă cu inductori puternici ai CYP3A4/5 precum rifampicină, ... CYP3A4 şi/sau ai CYP3A5 poate reduce concentraţiileplasmatice

ANEXA I REZUMATUL CARACTERISTICILOR … · Administrare concomitentă cu inductori puternici ai CYP3A4/5 precum rifampicină, ... CYP3A4 şi/sau ai CYP3A5 poate reduce concentraţiileplasmatice

Documents

PRILOG I. - European Medicines Agency · CYP3A4/5 i P-glikoproteina) ili nakon 6 dana flukonazola 200 mg/dan (inhibitor CYP2C9, CYP2C19 i CYP3A4/5) u zdravih ispitanika, opaženo

PRILOG I. - European Medicines Agency · CYP3A4/5 i P-glikoproteina) ili nakon 6 dana flukonazola 200 mg/dan (inhibitor CYP2C9, CYP2C19 i CYP3A4/5) u zdravih ispitanika, opaženo

Documents

Rappresentazione del CITOCROMO CYP3A4, …...Rappresentazione del CITOCROMO CYP3A4, l'enzima maggior-mente coinvolto nella degradazione dei farmaci e nelle Interazio-ni farmacologiche

Rappresentazione del CITOCROMO CYP3A4, …...Rappresentazione del CITOCROMO CYP3A4, l'enzima maggior-mente coinvolto nella degradazione dei farmaci e nelle Interazio-ni farmacologiche

Documents

€¦ · 50 1% 55-370b IJ7jY5P CYP3A4 CYP3A4 CtlBD 1) 1) (D 95370b cnB CYP3A4 ct1BD æn-so 22)

€¦ · 50 1% 55-370b IJ7jY5P CYP3A4 CYP3A4 CtlBD 1) 1) (D 95370b cnB CYP3A4 ct1BD æn-so 22)

Documents

SUTENT. SUTENTreduction for SUTENT to a minimum of 37.5 mg (GIST and RCC) or 25 mg (pNET) daily should be considered if SUTENT must be co-administered with a strong CYP3A4 inhibitor

SUTENT. SUTENTreduction for SUTENT to a minimum of 37.5 mg (GIST and RCC) or 25 mg (pNET) daily should be considered if SUTENT must be co-administered with a strong CYP3A4 inhibitor

Documents

COMMON TOXICITY CRITERIA MANUAL - National … · Common Toxicity Criteria Manual 1 COMMON TOXICITY CRITERIA QUICK REFERENCE Definition of Adverse Event • Toxicity – Toxicity

COMMON TOXICITY CRITERIA MANUAL - National … · Common Toxicity Criteria Manual 1 COMMON TOXICITY CRITERIA QUICK REFERENCE Definition of Adverse Event • Toxicity – Toxicity

Documents

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI · pasaj hepatic, mediată de enzima CYP3A4. Se recomandă precauţie la administrarea concomitentă cu inhibitori puternici ai CYP3A4

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI · pasaj hepatic, mediată de enzima CYP3A4. Se recomandă precauţie la administrarea concomitentă cu inhibitori puternici ai CYP3A4

Documents

pp 1-2zq · 2011. 9. 7. · juice, itraconazole, ketoconazole, and verapamil may increase colchicine levels and the subsequent risk of toxicity [5]. Many CYP3A4 inhibitors also inhibit

pp 1-2zq · 2011. 9. 7. · juice, itraconazole, ketoconazole, and verapamil may increase colchicine levels and the subsequent risk of toxicity [5]. Many CYP3A4 inhibitors also inhibit

Documents

Mechanism of action Kinase inhibitor Tyrosine kinase inhibitor Proteasome inhibitor Kinase inhibitor, targets HER2 Immunomodulatory drug Kinase inhibitor Non-steroidal aromatase

Mechanism of action Kinase inhibitor Tyrosine kinase inhibitor Proteasome inhibitor Kinase inhibitor, targets HER2 Immunomodulatory drug Kinase inhibitor Non-steroidal aromatase

Documents

Utjecaj polimorfizama CYP3A4/5 i CYP2D6 na serumske

Utjecaj polimorfizama CYP3A4/5 i CYP2D6 na serumske

Documents

Selection of Alternative CYP3A4 Probe Substrates for ...dmd.aspetjournals.org/content/dmd/early/2010/03/04/dmd.110.0320… · develop a strategy for selecting alternate CYP3A4 probe

Selection of Alternative CYP3A4 Probe Substrates for ...dmd.aspetjournals.org/content/dmd/early/2010/03/04/dmd.110.0320… · develop a strategy for selecting alternate CYP3A4 probe

Documents

Toxicity and Disruptive Impacts of Novaluron, A Chitin Synthesis Inhibitor, on Development and Metamorphosis of The Olive Leaf Moth Palpita unionalis

Toxicity and Disruptive Impacts of Novaluron, A Chitin Synthesis Inhibitor, on Development and Metamorphosis of The Olive Leaf Moth Palpita unionalis

Education

Kelompok 3. Enzyme Inhibitor Pengertian ; Inhibitor Inhibitor

Kelompok 3. Enzyme Inhibitor Pengertian ; Inhibitor Inhibitor

Documents

Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the

Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the

Documents

Studies on Drug Interactions between CYP3A4 Inhibitors and

Studies on Drug Interactions between CYP3A4 Inhibitors and

Documents

Grapefruit: Inhibits CYP3A4

Grapefruit: Inhibits CYP3A4

Documents

Evaluating A Potential CYP3A4 Selective Inhibitor With MD

Evaluating A Potential CYP3A4 Selective Inhibitor With MD

Documents

Potent competitive inhibition of human ribonucleotide ... · inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity

Potent competitive inhibition of human ribonucleotide ... · inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity

Documents

Covid-19 U.S. Epidemiology, Diagnostic, and Pathogenesis ... · max > 10 µM –Plasma t 1/2 0.66-1h after infusion •Renally excreted; CYP3A4 inhibitor but significant DDIs unlikely

Covid-19 U.S. Epidemiology, Diagnostic, and Pathogenesis ... · max > 10 µM –Plasma t 1/2 0.66-1h after infusion •Renally excreted; CYP3A4 inhibitor but significant DDIs unlikely

Documents

FARMAKOVIGJILENCAomi.al/.../materialet-e-trajnimit-te-farmakovigjilences.docx · Web viewKonsiderohet si makrolidi me i sigurt per terapi sebashku me agjent qe bllokojne CYP3A4. CYP3A4

FARMAKOVIGJILENCAomi.al/.../materialet-e-trajnimit-te-farmakovigjilences.docx · Web viewKonsiderohet si makrolidi me i sigurt per terapi sebashku me agjent qe bllokojne CYP3A4. CYP3A4

Documents

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI · CYP3A4 joacă un rol minor în metabolismul enzalutamidei. După administrarea pe cale orală a unui inhibitorul puternic al CYP3A4,

ANEXA I REZUMATUL CARACTERISTICILOR PRODUSULUI · CYP3A4 joacă un rol minor în metabolismul enzalutamidei. După administrarea pe cale orală a unui inhibitorul puternic al CYP3A4,

Documents

Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University

Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University

Documents

Jordi Fontcuberta Unitat d’Hemostasia i Trombosi Servei .... Jordi...Inhibidor bomba protones Inhibidor potente de CYP3A4 y glicoproteina P Inhibidor potente de CYP3A4 y glicoproteina

Jordi Fontcuberta Unitat d’Hemostasia i Trombosi Servei .... Jordi...Inhibidor bomba protones Inhibidor potente de CYP3A4 y glicoproteina P Inhibidor potente de CYP3A4 y glicoproteina

Documents

An NMR-based pharmacometabonomic study of CYP3A4 activity

An NMR-based pharmacometabonomic study of CYP3A4 activity

Documents